Body Weight

The dual incretin agonist tirzepatide was superior to titrated insulin degludec for adults with type 2 diabetes, with greater reductions in HbA1c and body weight at week 52 and lower risk for hypoglycemia, data published in The Lancet show.

Failure to meet certain emotional developmental milestones between ages 3 to 7 years appeared to increase risk for broad anorexia nervosa, according to results of a cohort study published in JAMA Psychiatry.

Researchers saw higher reduction in steatosis and body weight with the low-carb high-fat and 5:2 diets compared with the standard of care in patients with nonalcoholic fatty liver disease, according to a presentation at the International Liver Congress.

Adults with type 2 diabetes in South Korea had lower HbA1c and body weight 6 months after switching from insulin to the GLP-1 receptor agonist dulaglutide, according to a study published in Diabetes/Metabolism Research and Reviews.

The GIP/GLP-1 receptor agonist tirzepatide significantly reduced HbA1c and body weight compared with insulin glargine for adults with type 2 diabetes at high cardiovascular risk, according to new data from the SURPASS trial program.

Maternal nutrition during pregnancy may have a long-term impact on children’s weight trajectories, researchers reported.

Among adults with type 2 diabetes, inhaled insulin was associated with HbA1c reductions similar to those with insulin aspart, fewer hypoglycemic episodes and lower body weight, according to a study published in Endocrine Practice.

Within couples, there was often similar adherence or nonadherence to ideal CV health behaviors, which may represent an opportunity for targeted risk factor modification, researchers reported.

Adults with poorly controlled type 2 diabetes assigned higher, investigational doses of the GLP-1 receptor agonist dulaglutide experienced greater improvements in glycemic response and body weight compared with those assigned the currently approved dose of 1.5 mg weekly, with no new safety signals observed, according to findings from the AWARD-11 trial published in the Journal of the Endocrine Society.

Adults with obesity who wore a heavyweight vest — corresponding to 11% of their body weight — daily for 3 weeks experienced a reduction in body weight and fat mass compared with similar adults who wore a 1% lightweight vest, according to data from a proof-of-concept study.